The Taiwan Food and Drug Administration (TFDA) has granted CTL Amedica a license for its MATISSE anterior cervical interbody fusion (ACIF) cage system, allowing the company to market the device in the country.
Daniel Chon, CEO of CTL Amedica, said: “We’re honoured by the TFDA’s approval and are excited to work with our Taiwan distributor partner to make this important spinal technology readily available throughout Taiwan. We hope to have it commercially available throughout Taiwan in the coming months and eventually in markets throughout Asia.”
Named after the famous French impressionist painter Henri Matisse, the MATISSE ACIF cage system designed to accommodate a wide range of patient anatomies and surgeon preferences. It features streamlined instrumentation and a tapered leading edge for easy insertion, as well as, a large graft area to further promote bone fusion, say the company.
The MATISSE ACIF cage system is available in numerous footprints, heights, lordotic angles and materials, including titanium, PEEK and titanium-plated PEEK. Both titanium and titanium-plated PEEK feature CTL Amedica’s proprietary TiCro surface technology.